NTT-LTD.
NTT Ltd., a leading IT infrastructure and services company, and Cisco, a worldwide leader in technology, today announced a collaboration to develop and deploy joint solutions that empower organizations to improve operational efficiencies and advance sustainability goals.
Leveraging NTT’s Edge as a Service portfolio and Cisco’s IoT capabilities, solutions developed by the two companies will offer real-time data insights, enhanced security, improved decision-making, and reduced operational costs through predictive maintenance, asset tracking, and supply chain management capabilities.
The companies will deliver solutions that combine NTT’s Managed Services expertise, automation capabilities at the edge, and the management of complex IT environments, with Cisco’s IoT capabilities, including Low Power Wide Area Networking (LoRaWAN).
As part of today’s news, NTT has bolstered its IoT consulting and services business that brings together more than 1000 practitioners and 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories, utilities and more. NTT has already trained more than 500 Cisco sales experts to accelerate the companies’ combined capabilities and go-to-market efforts.
“We are accelerating our IoT business initiatives to deliver a powerful portfolio of repeatable services that can be tailored to meet customer demand for these kinds of solutions. We’re in a unique position,” said Devin Yaung, SVP of Group Enterprise IoT Products and Services at NTT.
“We are excited to work together to help transition our customers to this IoT-as-a-Service model so they can quickly realize the business benefits across industries and around the globe,” said Samuel Pasquier, VP of Product Management, Industrial IoT Networking, Cisco.
Transforming Water Management Through Smart Solutions
NTT and Cisco are developing solutions and go-to-market offers focusing on industries such as manufacturing, transportation, and healthcare, where there is a growing demand for edge computing and IoT solutions. The two companies are already deploying this advanced ‘ruggedized’ service to several customers including Compagnie Intercommunale Liégeoise des Eaux (CILE), a public water distribution company located in Belgium.
NTT and Cisco have deployed thousands of LoRaWAN sensors across CILE’s infrastructure to provide remote visibility that improves operational efficiencies related to water quality, consumption, distribution, and maintenance. The solution also includes advanced technologies such as smart distribution networks, remote reading through smart meters, smart grid for remote management, connected IoT objects, and AI, delivered as a managed service. The network also provides the building blocks to support other sustainability use cases such as waste management, parking management, water quality and street light controls.
“At CILE, we provide critical infrastructure for 24 cities in Belgium, which means efficiency, security and reliability are key," said William de Angelis, CIO and CDO at CILE. “With NTT and Cisco’s support, we have real-time insights into our facilities and distribution networks, including faster detection of leaks, allowing us to respond to issues instantaneously and expand the network to other sustainability use cases.”
NTT Ramps Up IoT Consulting and Services Business
In a move to prioritize and scale IoT for clients and partners, NTT has activated an IOT-dedicated business unit bringing together deep expertise and capabilities from around the globe. The team of 1,000 consultants, engineers, enterprise architects, and sustainability experts will build, deploy, and manage more than 100 use cases in areas such as connected cars, fleet management, predictive maintenance, smart cities, digital twins, connected factories and more.
“We’re doubling down on NTT’s IoT capabilities to meet customer demand,” continued Yaung. “What we’re doing is pulling together our collective knowledge and skillsets, and putting the full power of NTT behind it, to better service our customers and the increasing need to outfit or retrofit their organizations with the connectivity and visibility they need to improve day-to-day business operations.”
The global IoT market is expected to grow 19 percent in 2023, with a potential market size of $483 billion by 2027.
#ENDS#
About NTT Ltd.
As part of NTT DATA, a USD 30 billion IT services provider, NTT Ltd. is a leading IT infrastructure and services company serving 65% of the Fortune Global 500 and more than 75% of the Fortune Global 100. We lay the foundation for organizations’ edge-to-cloud networking ecosystem, simplify the complexity of their workloads across multicloud environments, and innovate at the edge of their IT environments where networks, cloud and applications converge. We offer tailored infrastructure and ensure consistent best practices in design and operations across all of our secure, scalable and customizable data centers. On the journey towards a software-defined future, we support organizations with our platform-delivered infrastructure services. We enable a connected future.
Visit us at services.global.ntt
About Cisco
Cisco (NASDAQ: CSCO) is the worldwide leader in technology that powers the Internet. Cisco inspires new possibilities by reimagining your applications, securing your data, transforming your infrastructure, and empowering your teams for a global and inclusive future. Discover more on The Newsroom and follow us on Twitter at @Cisco.
Cisco and the Cisco logo are trademarks or registered trademarks of Cisco and/or its affiliates in the U.S. and other countries. A listing of Cisco's trademarks can be found at www.cisco.com/go/trademarks. Third-party trademarks mentioned are the property of their respective owners. The use of the word partner does not imply a partnership relationship between Cisco and any other company.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230518005431/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models5.1.2026 14:54:00 CET | Press release
Falcon H1R 7B Packs Advanced Reasoning into a Compact 7 Billion Parameter Model Optimized for Speed and Efficiency TII’s Latest AI Model Outperforms Larger Rivals from Microsoft, Alibaba, and NVIDIA on Key Benchmarks The Technology Innovation Institute (TII), the applied research pillar of Abu Dhabi’s Advanced Technology Research Council (ATRC), has announced the release of Falcon H1R 7B, a next-generation AI model that takes a significant step toward making advanced AI more accessible than ever, by delivering world-class reasoning performance in a compact, efficient, and openly available format. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260105981339/en/ TII Launches Falcon Reasoning: Best 7B AI Model Globally, Also Outperforms Larger Models (Graphic: AETOSWire) With just 7 billion parameters, Falcon H1R 7B challenges and, in many cases, outperforms larger open-source AI models from around the world, including models fr
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom